// App-Quantinova.ai

e16514 : Clinical activity of ONC201 in metastatic castrate resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Mark N. Stein

Principal Investigators

  • Howard Kaufman

  • Cyril Benes

  • Martin Stogniew

  • Wolfgang Oster

  • Joshua E. Allen

  • Bruce George Haffty

  • Joseph R. Bertino

Medical Centers

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Oncoceutics, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic castration-resistant prostate cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • TIC 10

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • NA

Study Id's

  • NCT02324621

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved